• Eric L Simpson, Jane R Parnes, Dewei She, Sarah Crouch, William Rees, May Mo, and René van der Merwe.
• Oregon Health and Science University, Portland, Oregon. Electronic address: simpsone@ohsu.edu.
• J. Am. Acad. Dermatol. 2019 Apr 1; 80 (4): 1013-1021.

BackgroundTezepelumab (AMG 157/MEDI9929), a first-in-class monoclonal antibody, targets thymic stromal lymphopoietin, a cytokine that is implicated in the pathogenesis of atopic dermatitis (AD).ObjectiveWe sought to evaluate the efficacy and safety of tezepelumab in adults with moderate to severe AD.MethodsIn this phase 2a study (NCT02525094), 113 patients were randomized 1:1 to subcutaneous tezepelumab 280 mg or placebo every 2 weeks, plus class 3 topical corticosteroids (TCS). The primary endpoint was the week 12 response rate for a ≥50% reduction in the Eczema Area and Severity Index (EASI50). Secondary endpoints including EASI75, Investigator's Global Assessment, SCORAD 50, SCORAD 75, pruritus numeric rating and 5-D itch scales, and exploratory endpoints (including EASI90) were assessed at weeks 12, and 16 (post hoc).ResultsA numerically greater percentage of tezepelumab plus TCS-treated patients achieved EASI50 (64.7%) versus placebo plus TCS (48.2%; P = .091). Numerical improvements over placebo were demonstrated for week 12 secondary and exploratory endpoints, with further improvements at week 16. Treatment-emergent adverse events were similar between treatment groups.LimitationsGreater than expected response rates in placebo-treated patients were possibly attributable to TCS.ConclusionAlthough not statistically significant, numerical improvements over placebo for all week 12 endpoints were demonstrated, with greater week 16 responses.Copyright © 2018 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

48 keywords...

hide…